Last month, Healthscope (ASX:HSO) announced it had experienced slower-than-expected hospital revenue growth for the quarter. The announcement prompted a wave of selling, with the share price falling around 30%. Does this present a buying opportunity? Given the metrics of the private hospital industry, we think so. For years, we have rued the absence of value opportunities in the healthcare sector. In fact, when we set up Montgomery we put a basket of nine companies in a special category – a category that recognized companies that had NEVER been available below our most conservative estimates of their intrinsic value and therefore required special treatment and an adjustment to our discount rates in order to at least occasionally be available at a price approximating a rational valuation.